Danielle Brill
Stock Analyst at Raymond James
(1.88)
# 2,939
Out of 4,784 analysts
75
Total ratings
34.38%
Success rate
-8.72%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Strong Buy | $20 → $52 | $12.47 | +317.00% | 6 | Dec 10, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $65 | $18.65 | +248.53% | 1 | Nov 20, 2024 | |
| DNLI Denali Therapeutics | Reinstates: Market Perform | n/a | $14.78 | - | 1 | Oct 10, 2024 | |
| BMRN BioMarin Pharmaceutical | Reinstates: Outperform | $79 | $71.44 | +10.58% | 1 | Oct 10, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $18 | $7.83 | +129.89% | 1 | Oct 10, 2024 | |
| NBIX Neurocrine Biosciences | Reinstates: Outperform | $155 | $113.16 | +36.97% | 5 | Oct 10, 2024 | |
| IMVT Immunovant | Reinstates: Outperform | $36 | $18.37 | +95.97% | 4 | Oct 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Reinstates: Outperform | $40 | $33.19 | +20.52% | 7 | Oct 10, 2024 | |
| SRPT Sarepta Therapeutics | Reinstates: Outperform | $150 | $70.41 | +113.04% | 3 | Oct 10, 2024 | |
| BIIB Biogen | Reinstates: Market Perform | n/a | $138.37 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $8.28 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $492.69 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $589.15 | +2.69% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $17.07 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $34.26 | +45.94% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $30.28 | +68.43% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $43 | $52.36 | -17.88% | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $0.38 | +1,212.34% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $54.24 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.31 | - | 5 | Jun 27, 2023 |
uniQure
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $12.47
Upside: +317.00%
Tectonic Therapeutic
Nov 20, 2024
Initiates: Outperform
Price Target: $65
Current: $18.65
Upside: +248.53%
Denali Therapeutics
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $14.78
Upside: -
BioMarin Pharmaceutical
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $71.44
Upside: +10.58%
REGENXBIO
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $7.83
Upside: +129.89%
Neurocrine Biosciences
Oct 10, 2024
Reinstates: Outperform
Price Target: $155
Current: $113.16
Upside: +36.97%
Immunovant
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $18.37
Upside: +95.97%
Harmony Biosciences Holdings
Oct 10, 2024
Reinstates: Outperform
Price Target: $40
Current: $33.19
Upside: +20.52%
Sarepta Therapeutics
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $70.41
Upside: +113.04%
Biogen
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $138.37
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $8.28
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $492.69
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $589.15
Upside: +2.69%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $17.07
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $34.26
Upside: +45.94%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $30.28
Upside: +68.43%
May 10, 2024
Maintains: Outperform
Price Target: $40 → $43
Current: $52.36
Upside: -17.88%
Nov 14, 2023
Maintains: Outperform
Price Target: $9 → $5
Current: $0.38
Upside: +1,212.34%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $54.24
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.31
Upside: -